Company news
Cannabis Bioscience International Holdings, Inc. (OTC:CBIH) news
Cannabis Bioscience International Holdings, Inc. news releases on 6ix. Latest, Jul 20, 2026: CBIH Unveils Cannabinoid-Based Intranasal Platform…
Press releases & updates
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
July 20, 2026
Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products
July 15, 2026
CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
July 6, 2026
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
June 22, 2026
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
June 15, 2026
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
June 8, 2026
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
June 1, 2026
Cannabis Bioscience International Holdings Seeks Participation in Renewed DEA Marijuana Rescheduling Hearing
May 13, 2026
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
January 21, 2026
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
January 12, 2026
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
January 5, 2026
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
December 29, 2025
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
December 22, 2025
CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
December 15, 2025
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
October 13, 2025
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
October 6, 2025
CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center
September 29, 2025
Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now
January 13, 2025
Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification
January 12, 2025
Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products
January 5, 2025
CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing
December 15, 2024
A Letter from the Desk of CBIH
December 8, 2024
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
December 3, 2024
CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing
December 1, 2024
CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip
November 24, 2024
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
November 17, 2024
Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
November 11, 2024
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy
November 3, 2024
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
July 14, 2024
CBIH Charts Path to Future Leadership in Cannabis Medicine
July 7, 2024
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
June 30, 2024
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
June 25, 2024
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
June 16, 2024
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
June 4, 2024
CBIH Engages Prestigious Law Firm for its First Patent Applications
May 19, 2024
CBIH Welcomes New Treasurer and Director, Mr. John E. Jones
May 5, 2024
CBIH Commences Clinical Trials of Osteoarthritis Injection "Orthocann"
March 19, 2024
CBIH Announces the Retirement of One Billion Shares
March 5, 2024
Brian Cuban Joins Cannabis Bioscience International Holdings as an Advisory Board Member
February 25, 2024
Cannabis Bioscience International Holdings, Inc. Announces Engagement of Bull in Advantage as its Investor Relations Firm
February 19, 2024
A Letter From Cannabis Bioscience International Holdings CEO Dante Picazo Regarding Actual Progress and Plans for 2024
December 17, 2023
Cannabis Bioscience International Holdings Announces Effectiveness of Form S-1 Registration Statement
December 5, 2023
Cannabis Bioscience International Holdings (CBIH) Unveils Its Rebranding Through Its New and Innovative Website
September 10, 2023
FINRA Announces Approval for Corporate Name Change From China Infrastructure Construction Corp. to Cannabis Bioscience International Holdings and Ticker Symbol Change from CHNC to CBIH
August 20, 2023
CBIH Announces the Completion of the “Phase of Research and Discovery" for Its Phytotherapy Cancer Scientific Project
April 30, 2023
CHNC Announces to Its Allies the Rebranding and Name Change to Cannabis Bioscience International Holdings
April 23, 2023
Cannabis Bioscience International Holdings Announces the Appointment of Former Dallas Cowboy David Irving as Spokesperson of Our Company
April 16, 2023
Managemnt Rep Letter Q1, Q2 and Q3 Corrected
July 14, 2022
Manahement Rep Letter Q1, Q2 and Q3
July 14, 2022
CHNC Completes Review of Its First Three Fiscal Quarters
July 12, 2022